MedTrace Logo

Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation

NCT05790213 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2025-06-12

No results posted yet for this study

Summary

The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).

Conditions

Interventions

DRUG

Androgen Deprivation Therapy (ADT)

ADT will be given for 3 months. Participants will receive a standard ADT as chosen by their study doctor.

PROCEDURE

Focal prostate ablation (focal therapy)

Focal prostate ablation (focal therapy) is a surgical procedure to destroy cancer cells by destroying a portion of the prostate instead of the whole prostate.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Abhinav Sidana, MD · University of Chicago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-05
Primary Completion
2028-12-18
Completion
2028-12-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05790213 on ClinicalTrials.gov